Lizi Wu, Ph.D.
Lizi Wu, Ph.D., is the program co-leader of the Mechanisms of Oncogenesis (MOO) program.
The Wu lab investigates the molecular basis of cancer that aims to uncover novel cancer diagnostic and therapeutic approaches. Her research has been funded by the National Institutes of Health (NIH), Florida Department of Health and private foundations. She is active in teaching and mentoring trainees at all levels and has served on graduate admissions committees. Wu is an ad hoc reviewer for various grant agencies, including the NIH and multiple scientific journals, and an associate editor for the Molecular Therapy journal. She also serves on multiple committees, including the UF College of Medicine’s tenure and promotion committee, medical student interview committee and faculty council.
Daohong Zhou, M.D.
Daohong Zhou, M.D., is program co-leader.
He is a professor in the Department of Pharmacodynamics at the College of Pharmacy and a Professor in the Department of Radiation Oncology at the College of Medicine, University of Florida (UF) at Gainesville. He serves as the Associate Director for Translation and Drug Development and the Henry E. Innes Professorsip of Cancer Research at the UF Health Cancer Center. Dr. Zhou received his medical (1978-1983) and graduate (1983-1986) training from Yunyany Medical College of Tongji Medical University and Henan Medical University, respectively; and his postdoctoral training (1990-1992) at the Johns Hopkins University School of Medicine. Before he joined UF in 2018, he was a Professor of Pharmaceutical Sciences and the Deputy Director of the Division of Radiation Health at the College of Pharmacy and the Associate Director for Basic Research at the Winthrop P. Rockefeller Cancer Institute in the University of Arkansas for Medical Sciences (UAMS).
Dr. Daohong Zhou has published more than 100 peer reviewed scientific articles and book chapters. His research has been well supported by grants from various private and government funding agencies, including the National Cancer Institute (NCI) and National Institute of Allergy and Infectious Disease (NIAID). Dr. Daohong Zhou serves on several national and international peer review panels and as a reviewer for various scientific publications. He was a regular member of the Radiation Therapeutics and Biology Study Section at the National Institutes of Health (NIH) and a co-chair of the Panel Meeting for General Program of the Dept. of Health Sciences (Hematology) at the National Natural Science Foundation of China (NSFC). He is a councilor of the Radiation Research Society and a co-founder of Unity Biotechnology, a biotech that develops senolytic drugs for aging and age-related diseases.